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Abstract
Glycerol-3-phosphate acyltransferase-1 (GPAT1), which is located on the outer mitochondrial
membrane comprises up to 30% of total GPAT activity in the heart. It is one of at least four
mammalian GPAT isoforms known to catalyze the initial, committed, and rate limiting step of
glycerolipid synthesis. Because excess triacylglycerol (TAG) accumulates in cardiomyocytes in
obesity and type 2 diabetes, we determined whether lack of GPAT1 would alter the synthesis of
heart TAG and phospholipids after a 2-week high sucrose diet or a 3-month high fat diet. Even in
the absence of hypertriglyceridemia, TAG increased 2-fold with both diets in hearts from wildtype
mice. In contrast, hearts from Gpat1−/− mice contained 20–80% less TAG than the wildtype
controls. In addition, hearts from Gpat1−/− mice fed the high-sucrose diet incorporate 60% less
[14C]palmitate into heart TAG as compared to wildtype mice. Because GPAT1 prefers 16:0-CoA
to other long chain acyl-CoA substrates, we determined the fatty acid composition of heart
phospholipids. Compared to wildtype littermate controls, hearts from Gpat1−/− mice contained a
lower amount of 16:0 in phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine/
phosphatidylinositol and significantly more C20:4n6. Phosphatidylcholine and
phosphatidylethanolamine from Gpat1−/− hearts also contained higher amounts of 18:0 and 18:1.
Although at least three other GPAT isoforms are expressed in the heart, our data suggest that
GPAT1 contributes significantly to cardiomyocyte TAG synthesis during lipogenic or high fat
diets and influences the incorporation of 20:4n6 into heart phospholipids.
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Introduction
Regulation of triacylglycerol (TAG) and phospholipid synthesis plays a critical role in
diseases such as obesity, type 2 diabetes, and atherosclerosis. In the heart, excess TAG
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accumulation in cardiomyocytes is considered to be a marker for “lipotoxicity,” a condition
resulting in apoptosis of cardiomyocytes and ultimately, myocardial dysfunction [1–6].
Phospholipids, the major lipid component of cell membranes, not only serve a barrier
function, but also provide a major reservoir of signaling molecules such as lysophosphatidic
acid, phosphatidic acid, diacylglycerol and the arachidonate- and eicosapentanoate-derived
eicosanoids. In the heart, a change in the polyunsaturated fatty acid composition of
membrane phospholipids alters downstream signaling cascades [7,8], and mitochondrial
function in aging hearts [9], and is correlated with membrane dysfunction and decreased
contractility in rodent models of type 1 diabetes [10].
The initial and rate-limiting step in TAG and phospholipid synthesis is the GPAT catalyzed
acylation of sn-glycerol-3-phosphate with long-chain acyl-CoA. Historically, heart GPAT
activity was believed to result from the actions of two isoenzymes, one in the outer
mitochondrial membrane (GPAT1) and the other in the endoplasmic reticulum (microsomal
GPAT) [11]. GPAT1 activity is easily distinguished because, unlike microsomal GPAT, it is
not inhibited by sulfhydryl reagents such as N-ethylmaleimide (NEM) [12]. We recently
identified a second NEM-sensitive GPAT activity (GPAT2) in liver mitochondria from
Gpat1−/− mice [13] and cloned it [14], but it has not been characterized in the heart. The
NEM-sensitive endoplasmic reticulum isoforms, GPAT3 [15,16] and GPAT4 [17,18] are
also expressed in heart, but their contribution to heart glycerolipid synthesis has not been
studied. In heart total membrane preparations, NEM-sensitive activity comprises 70–90% of
total GPAT activity measured [11,19]. Unlike GPAT2, 3, and 4 which are NEM-sensitive
GPAT activities that do not exhibit chain length or saturation specificity for long chain acyl-
CoAs, GPAT1 prefers 16:0 three- to ten-fold more than other long-chain saturated or
unsaturated acyl-CoA substrates [20–22].
Although microsomal GPAT activity (GPAT 3 and 4) and the terminal enzymes for TAG
synthesis are all present in the endoplasmic reticulum, several studies suggest that the
critical isoform that regulates TAG synthesis is the mitochondrial GPAT1. In general, Gpat1
mRNA, protein, and activity in liver and adipose tissue increase with carbohydrate feeding
and with insulin stimulation via SREBP-1c, whereas microsomal activity does not change
[19,23–26]. The role for GPAT1 in up-regulating TAG synthesis is also supported by studies
of overexpressed rat GPAT1 in Chinese hamster ovary (CHO) cells and primary rat
hepatocytes. In CHO cells, over-expression of GPAT1 results in a 3.8-fold increase in
NEM-resistant GPAT activity, a 4-fold increase in [14C]oleate incorporation into TAG, and
a 30% decrease in [14C]oleate incorporation into phospholipids [27]. Similar results are
observed in primary rat hepatocytes, where a 13-fold increase in GPAT1 activity increases
both the TAG mass and [14C]oleate incorporation into TAG more than 2-fold [28]. Gpat1
null mice have lower hepatic TAG content, lower plasma TAG and very low density
lipoprotein TAG, and decreased secretion of TAG from liver [29]. Female Gpat1−/− mice
weigh less than controls and have reduced gonadal fat pad weights. These data strongly
suggest that GPAT1 is required for the normal synthesis of TAG in both fat cells and
hepatocytes.
The role of GPAT1 in cardiomyocytes has not been established. Because the product of
GPAT, lysophosphatidic acid, is a universal precursor for all glycerolipids, we hypothesized
that diminished GPAT1 activity would alter the metabolism of myocardial TAG and
phospholipids, which are critically required for energy production and the synthesis of
myocardial membranes.
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Animal protocols were approved by the University of North Carolina at Chapel Hill
Institutional Animal Care and Use Committee. Heterozygous (Gpat1−/+) mice were bred,
and wildtype and Gpat1−/− littermates were genotyped as described previously [29]. Mice
were housed on a 12-h/12-h light/dark cycle with free access to water and defined isocaloric
diets from Research Diets, Inc. The control diet (D12328) contained 16.4% protein, 12%
maltodextrin, 60% corn starch, 4% soybean oil, and 6.5% hydrogenated coconut oil. The
high sucrose diet (D12329) contained 16.4% protein, 12% maltodextrin, 60% sucrose, 4%
soybean oil, and 6.5% hydrogenated coconut oil. The high fat diet (D12330) contained
16.4% protein, 12% maltodextrin, 12.5% corn starch, 4% soybean oil, and 54%
hydrogenated coconut oil. At 2 months of age, wildtype and Gpat1−/− mice were placed in
one of 3 feeding groups: control diet for 2 weeks, high sucrose diet for 2 weeks, or high fat
diet for 3 months. F2 mice (50% C57BL/6, 50% SvEv129) were used for the high fat diet
study and to examine cardiac lipid composition. Mice backcrossed 6 generations to the
C57BL/6 background were used in the high sucrose feeding study.
RNA isolation and reverse transcriptase PCR
Hearts from two wildtype, two heterozygous and two Gpat1 knockout mice were trimmed of
fat and flash frozen in liquid nitrogen. RNA was isolated using the RNeasy mini kit for
fibrous tissue (Qiagen) according to manufacturer’s protocol. Briefly, frozen whole hearts
(≈ 150 mg) were homogenized using a rotor stator homogenizer in 1.5 ml Buffer RLT + β-
mercaptoethanol. Three hundred μl homogenate was used for RNA isolation. Heart RNA
was subjected to reverse transcriptase PCR to determine the presence or absence of Gpat1
and neomycin (neo) RNA transcripts. The cDNA was generated using the Superscript first-
strand synthesis system for RT-PCR (Invitrogen), with oligo(dT)12–18 primer according to
manufacturer’s protocol. PCR primers used were Gpat1 forward (5′ ACA GTT GGC ACA
ATA GAC GT), Gpat1 reverse (5′ GAA GAT CTC CAG GAA CTG CT), and neo reverse
(5′ TTA TGG CGC GCC ATC GAT CT). PCR products were analyzed on a 1.2 % agarose
gel.
Isolation of heart total membrane and mitochondria
Hearts were trimmed of valves and external fat, minced, and homogenized with 10 up-and-
down strokes in a Teflon-glass homogenizer in 10 mM Tris-HCl pH 7.4, 250 mM sucrose, 1
mM DTT, and 1 mM EDTA. Large debris and nuclei were removed by centrifugation for 5
min at 600 × g. Total membranes were obtained by centrifuging the supernatant for 1 h at
100,000 × g. For mitochondrial isolation, hearts from 4 mice were trimmed and
homogenized as described above. Mitochondria were obtained by centrifuging the post-
nuclear supernatant at 10,300 × g for 10 min. The microsomal fraction was acquired by
centrifuging the supernatant for 1 h at 100,000 × g. Protein concentrations were determined
by the bicinchonic acid method (Pierce) using bovine serum albumin as the standard. Purity
of the subcellular fractions was determined by measuring the activity of marker enzymes,
NADH cytochrome c reductase [30] and cytochrome c oxidase (cytochrome c oxidase kit,
Sigma) for endoplasmic reticulum and mitochondria, respectively.
Assay for glycerol-3-phosphate acyltransferase
sn-[2-3H]glycerol-3-phosphate was synthesized enzymatically from [2-3H]glycerol (1 mCi/
ml) and purified as described previously [31]. GPAT activity was assayed at room
temperature in a 200 μl mixture containing 75 mM Tris-HCl pH 7.5, 4 mM MgCl2, 1 mg/ml
bovine serum albumin (essentially fatty acid-free), 1 mM DTT, 8 mM NaF, 800 μM [3H]
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glycerol-3-phosphate and 80 μM palmitoyl-CoA [32]. The reaction was initiated by adding
20–60 μg mitochondrial protein that had been incubated on ice for 15 min in the absence or
presence of the indicated concentrations of NEM.
Blood chemistries and lipids
Mice were fasted 4 h, anesthetized with Avertin, and bled retroorbitally. Plasma TAG (TG,
Stanbio Laboratory), total cholesterol (Cholesterol CII, Wako Chemical), free fatty acids
(NEFA, Wako Chemical), and glucose (Glucose Trinder, Sigma) were determined by
enzymatic colorimetric methods. Insulin was determined by radioimmunoassay (Linco). To
determine VLDL secretion rates, mice were fasted for 4 h and then given 10% fructose to
drink. Plasma was collected for TAG measurements at time zero and at 20, 40, 60, 80, and
120 min after I.V. injection of 20 mg Triton WR-1339 (Tyloxapol, Sigma) in a volume of
200 μl. At the final time point, mice were euthanized and livers were collected and weighed.
The rate of VLDL secretion was expressed as the concentration of TAG secreted (mg per dl)
per gram of liver.
Heart triacylglycerol
Lipids were extracted [33] from frozen hearts. One ml of lipid extract was dried in a
SpeedVac concentrator and dissolved in 200 μl isopropyl alcohol containing 1% Triton
X-100. TAG concentration was determined using an enzymatic colorimetric method
(Stanbio Laboratory).
[14C]palmitate incorporation into heart triacylglycerol
[14C]palmitate incorporation into heart TAG was performed as described previously [34,35].
Mice were injected retro-orbitally with 1 μCi [14C]palmitate complexed with 5% BSA.
Blood was collected from the tail vein 5 and 30 min after injection of radiolabeled fatty acid.
[14C] in plasma was determined by scintillation counting. At 32 min post-injection, mice
were euthanized. The heart was exposed, nicked near the aorta, perfused with 0.9% saline
through the left ventricle, excised, rinsed in 0.9% saline to remove all blood, and then frozen
in liquid N2. Frozen tissue was pulverized into a fine powder and homogenized as described
above. An aliquot of homogenized tissues was set aside for to determine protein
concentration. Lipids were extracted from homogenized tissue as described above. Neutral
lipids were separated by TLC with authentic standards for FA, DAG, and TAG (Avanti
Polar Lipids) on LKD5 silica plates (Whatman) developed in hexane:ethyl ether: aceteic
acid (80:20:2 by vol). [14C] incorporated into TAG was quantified using Bioscan
instrumentation and normalized to the protein concentration and dose of [14C] counted in
plasma.
Fatty acid analysis
Lipids from wildtype and Gpat1−/− (SvEv129 background) plasma and heart (100 mg) were
extracted after a 4 h fast in the presence of authentic internal standards [36] using
chloroform: methanol (2:1 v/v). Individual lipid classes were separated by preparative thin
layer chromatography [37]. Isolated lipid classes were transesterified in 3 N methanolic HCl
in a sealed vial under nitrogen atmosphere at 100 °C for 45 min. The resulting fatty acid
methyl esters were extracted with hexane containing 0.05% butylated hydroxytoluene and
then separated and quantified by capillary gas chromatography using a gas chromatograph
(Hewlett Packard model 6890) equipped with a 30 m DB 225MS capillary column (J&W
Scientific) and a flame ionization detector [37].
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Data are presented as means ± SD. Significant differences between groups were analyzed by
two-tailed Student’s t-test.
Results and Discussion
GPAT catalyzes the initial, committed, and rate limiting step in glycerolipid synthesis.
Previous studies show that GPAT1 controls TAG synthesis in liver and adipose tissue in
response to physiological signals [16,19,23–25], and that when GPAT1 is absent in liver, the
liver phospholipid fatty acid composition is altered [29,38]. Therefore, we asked whether the
relatively low GPAT1 activity in heart was functionally important for TAG accumulation
and phospholipid fatty acid composition.
Hearts from GPAT1−/− mice lack GPAT1 mRNA, but retain NEM-resistant GPAT activity in
mitochondria
Mice lacking GPAT1 weigh less than controls, have reduced gonadal fat pad weights, and
lower hepatic TAG, plasma TAG, and VLDL secretion [29]. These mice also have a higher
rate of hepatic fatty acid oxidation [39], and remain insulin sensitive on a high fat diet [39].
In liver from knockout mice, Gpat1 mRNA is undetectable and NEM-resistant GPAT
activity is reduced >90% [29]. In Gpat1−/− mice, a novel NEM-sensitive mitochondrial
GPAT activity (GPAT2) is detectable in liver mitochondria [13].
As expected, no Gpat1 transcript was detected in hearts from the knockout animals (Fig.
1A). To confirm the absence of GPAT1 activity, we assayed heart total membrane fractions
in the absence and presence of 1 mM NEM. In hearts from wildtype mice, the NEM-
resistant GPAT activity was 0.13 nmol/min/mg, 27% of the total (0.47 nmol/min/mg) (Fig.
1B). In Gpat1−/−hearts, total GPAT activity was diminished 40%, confirming the absence of
GPAT1. However, 1 mM NEM failed to inhibit all the remaining GPAT activity, suggesting
the presence of a novel NEM-resistant isoform.
To determine whether this new NEM-resistant activity was microsomal or mitochondrial,
we assayed highly pure microsomal and mitochondrial fractions. GPAT activity from
wildtype and Gpat1−/− mice was identical in heart microsomes (data not shown). In heart
mitochondria, an NEM inhibition curve using 0 to 10 mM showed that maximal inhibition
occurred with 1 mM NEM in both genotypes (Fig. 1D). In wildtype mitochondria, 43% of
the GPAT activity was NEM-resistant (Fig. 1C). However, although the total mitochondrial
activity in Gpat1−/− hearts was 57% less than the activity measured in mitochondria from
wildtype mice, 1 mM NEM only decreased this activity 55% to 0.11 nmol/min/mg protein
(Fig. 1C). These data are contrary to our findings in liver mitochondria, where we found that
1 mM NEM treatment of liver mitochondria from Gpat1−/− mice completely inhibited all
GPAT activity indicating the absence of NEM-resistant GPAT activity [13]. Because the
other cloned GPAT isoforms (2 – 4) are inhibited by NEM [14,15,18], our data suggest the
presence of a novel non-GPAT1 NEM-resistant GPAT activity in heart mitochondria.
Absence of GPAT1 diminishes myocardial TAG accumulation in response to a high
sucrose diet
Although our studies on heart TAG synthesis are complicated by the presence of multiple
GPAT isoforms (GPAT1-4) [14,15,17,18,40], the Gpat1−/− mice still express significantly
lower myocardial GPAT activity. Because GPAT1 has an established role in regulating
TAG synthesis in liver, we asked whether GPAT1 might also regulate myocardial TAG
accumulation under lipogenic conditions such as sucrose-induced TAG accumulation in the
heart [41]. On the control diet, heart TAG content was similar in wildtype and Gpat1 null
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mice (Fig. 2A). Although 2 weeks of high sucrose feeding did not change GPAT1 mRNA
expression or NEM-resistant activity in mitochondria (data not shown), myocardial TAG
content increased 2-fold to 300 ng TAG/μg protein in male and female wildtype mice. In
sucrose-fed male Gpat1−/− animals, heart TAG content did not increase as compared to
mice fed the control diet (133 ng TAG/μg protein vs. 124 ng TAG/μg protein). In sucrose-
fed female knockout mice, myocardial TAG only increased 45% to 180 ng TAG/μg protein.
Myocardial TAG content in female Gpat1−/− may be greater than in male knockout
littermates because the female mice appear to be developing insulin resistance, as indicated
by significant increases in plasma insulin concentration (Table 1). The presence of
diminished heart TAG content in sucrose-fed mice indicated that GPAT1 may be an
important regulator of myocardial TAG synthesis.
Because Gpat1−/− mice have decreased VLDL secretion rates and lower plasma TAG than
wildtype littermates [29], we postulated that diminished delivery of TAG to the heart might
be responsible for the lower myocardial TAG content in heart from sucrose fed Gpat1−/−
mice. In sucrose-fed male Gpat1−/− mice, plasma TAG and cholesterol were significantly
lower than in wildtype mice (Fig. 3A, Table 1). However, in female Gpat1−/− mice, values
for plasma free fatty acid (FFA), TAG, and cholesterol did not differ significantly from
control or from treated wildtype mice (Fig. 3A, Table 1).
To determine whether the lower VLDL secretion rate reported in Gpat1−/− mice fed chow
[29] remained low in mice fed a lipogenic diet, VLDL secretion was measured in mice fed a
high sucrose diet for 2 weeks. The high sucrose diet increased liver TAG content 8-fold and,
compared to our previous study [29], increased the rate of VLDL synthesis 64% in wildtype
mice. Consistent with the diminished TAG synthesis observed in the absence of GPAT1,
sucrose-fed female Gpat1−/− mice had 40% lower content of liver TAG (43.7±3.3 mg/g
liver, n = 5) compared to wildtype controls (74.6±10.2 mg/g liver, n = 5). Although plasma
TAG and cholesterol concentrations were lower in male Gpat1−/− mice fed the sucrose diet
and unchanged in female mice (Table 1), VLDL secretion rates were 30% lower in both
sexes (Fig. 4A, B).
Surprisingly, even in the absence of hypertriglyceridemia (Fig. 3A), cardiac myocytes from
wildtype mice accumulated a significant amount of TAG (Fig. 2A). Although, myocardial
TAG accumulation is typically observed in pathophysiological conditions such as obesity
and diabetes [42–46], these data suggest that hypertriglyceridemia is not essential for heart
TAG accumulation.
Taken together, our data suggest that the lower content of TAG in Gpat1−/− hearts (Fig. 2A)
did not result from diminished entry of plasma fatty acid into the myocardial cells. Although
male Gpat1−/− mice had 24% lower plasma TAG (Fig. 3A), the plasma TAG concentration
in females was similar in knockout and wildtype animals, and VLDL secretion rates were
30% lower in both sexes. Thus, myocardial TAG content appeared to depend more on
GPAT1-initiated synthesis than on fatty acid delivery to the myocardium.
To confirm that myocardial TAG synthesis is diminished in Gpat1−/− hearts, we monitored
[14C]palmitate incorporation into heart TAG in vivo. Because male Gpat1−/− mice failed to
accumulate excess myocardial TAG with high-sucrose feeding (Fig. 2A), male wildtype and
Gpat1−/− mice fed the high-sucrose diet for 2 wks were injected with [14C]palmitate
complexed to BSA. After 30 min, Gpat1−/− hearts incorporated 60% less [14C] into TAG as
compared to wildtype mice (Fig. 5). Both the availability of plasma fatty acids and the
protein mediated uptake of fatty acids (ie via CD36, FABP) influence the rate of fatty acid
entry into the cardiomyocyte [47]. We did not determine if absence of GPAT1 altered
expression of proteins required for fatty acid entry, but plasma fatty acid concentrations
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were similar between wildtype and Gpat1−/− mice fed the high-sucrose diet (Table 1),
suggesting that the diminished rate of [14C] incorporation into heart TAG results from the
lack of GPAT1.
Absence of GPAT1 diminishes myocardial TAG accumulation in response to a high fat diet
High fat feeding, an established method for inducing obesity in rodents [48], is a second
method of increasing myocardial TAG content [49]. In an initial characterization of the
Gpat1−/−phenotype, F2 mice (50% C57BL/6J, 50% 129SvEv) were fed a high fat diet (58%
of kcal) for 3 months. The wildtype mice did not become obese or hypertriglyceridemic and
body weight of wildtype and Gpat1−/− mice increased only moderately (6–10 g), probably
because the study was performed on F2 mice which had a mixed background4 of 50%
C57BL/6J (obesity-prone [48]) and 50% 129SvEv (obesity-resistant; personal
communication Shelia Collins, Duke University). Despite the lack of obesity, the high fat
diet increased plasma TAG 30–70% (Fig. 3B) and plasma cholesterol 70–80% (Table 2) in
both wildtype and Gpat1−/− mice.
In male and female wildtype mice, the high fat diet increased myocardial TAG content 1.5-
to 2.2-fold above baseline to 213 and 323 ng TAG/μg protein, respectively (Fig. 2B). In
Gpat1−/−mice, however, heart TAG increased only 35% to 168 ng TAG/μg protein in males
and 80% to 223 ng TAG/μg protein in females (Fig. 2B). Greater myocardial TAG content
in female Gpat1−/− mice as compared to male knockout littermates may be due to the
significant rise in plasma insulin after 3 months of high-fat feeding (Table 2). Because the
increase in diet-induced plasma TAG concentration was the same in wildtype and knockout
mice, the lower cardiomyocyte TAG content in Gpat1 null mice suggests that GPAT1,
rather than an increase in fatty acid delivery, is required for the full increase in heart TAG
accumulation in response to a high fat diet.
Absence of GPAT1 alters heart phospholipid fatty acid composition
Myocardial phospholipid composition is altered in rats with heart dysfunction due to type 1
diabetes [10] and in aging rodents [9]. In aging rats, cardiolipin (CL) content is diminished,
resulting in impaired mitochondrial function, similar to that reported in liver from Gpat1−/−
mice [38]. Because the fatty acid (FA) composition of phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) is altered in liver from Gpat1−/− mice [29], we measured the
phospholipid FA composition in Gpat1−/− hearts. Compared to wildtype mice, the amount
of 16:0 in GPAT1−/− heart PC, PE, and PS/PI was 25%, 40%, and 45% lower, respectively
(Fig. 6 A–C), consistent with the preference of GPAT1 for 16:0-CoA [20–22]. PC from
Gpat1−/− hearts also contained more 18:0, 18:1n9, 20:4n6, and 22:0 (increases of 20%,
47%, 20%, and 28%, respectively) than wildtype controls (Fig. 6A). In PE from Gpat1−/−
hearts, 18:0, 18:1n9, and 20:4n6 were only 10–18% higher than controls (Fig. 6B). Different
FA were altered in PI/PS, with a dramatic 3.5-fold increase in 20:4n6 in Gpat1−/− hearts
compared to wildtype controls (Fig. 6C). PI/PS also contained 32% less 22:6n3. The fatty
acid composition of CL, a lipid critical for mitochondrial function, remained virtually
unchanged in Gpat1−/− hearts, but the minor species 22:0 was 85% higher than in wildtype
hearts (Fig. 6D). Because the heart derives fatty acid substrates from plasma lipoproteins,
and plasma TAG from Gpat1−/− mice shows similar changes in phospholipid FA
composition, with 40% less C16:0 and 35, 21, and 6% more 18:0, 18:1n9, and 18:2n6,
respectively, than wildtype controls (Fig. 6E), we cannot with certainty attribute these
changes to the absence of heart GPAT1. However, compared to wildtype mice heart PC, PE,
and PI/PS from Gpat1−/− mice contain 28%, 20%, and 350% more 20:4n6, respectively.
Because these increases were not observed in Gpat1−/− plasma TAG, it appears that heart
4Gpat1−/− mice backcrossed onto the C57BL/6J background become obese when fed a high fat, high sucrose diet for 4 months [55].
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GPAT1 plays an important role in establishing the fatty acid composition of its membrane
phospholipids. Higher 20:4n6 content was previously reported in both total liver
phospholipids [29] and liver mitochondrial phospholipids [38] from Gpat1−/− mice. In liver,
because the elevated 20:4n6 was primarily found at the sn-2 position, it was hypothesized
that the replacement of 16:0 with 18:0 and 18:1 at the sn-1 position might have altered
lysophospholipid remodeling at the sn-2 position [29]. Analyses of phospholipids typically
show 18:0 and 20:4 in the sn-1 and sn-2 positions, respectively, of the same phospholipid
molecule [50].
In Gpat1−/− hearts, the increased incorporation of 20:4n6 into phospholipids, particularly PI
and PS, could alter cardiac function. Arachidonic acid content in heart is important for
normal cardiac function especially in the sarcolemmal membrane in which 20:4 is normally
present on the cytoplasmic leaflet in PE, PS, and PI, and contributes to proper Ca2+ handling
and contractile function [10]. In streptozotocin-diabetic rats with diabetic cardiomyopathy, a
diminished 20:4 content is found in sarcolemmal PC, PE, and PS [10]. In addition,
arachidonate-derived eicosanoids have been linked to the development of cardiac fibrosis
[51]. The changes observed in myocardial PC, PE, and PI/PS provide strong evidence that
GPAT1 influences the final fatty acid composition of membrane phospholipids.
Absence of GPAT1 may result only in a mild myocardial phenotype because several GPAT
isoforms are present in the heart. Seventy percent of total heart GPAT activity is NEM-
sensitive and located in the endoplasmic reticulum [11,19]. This microsomal GPAT activity,
in part comprised of GPAT3 and 4 {Cao, 2006 #1199; Nagle, 2008 #1241}, is not regulated
concomitantly with increased heart TAG synthesis [19]. In heart mitochondria from
Gpat1−/−mice, the residual NEM-sensitive GPAT activity is probably GPAT2 [13,40],
whose contribution to TAG synthesis is unknown (Fig. 1C). In addition, the persistence of
NEM-resistant GPAT activity in Gpat1−/− heart mitochondria (Fig. 1C, D) suggests that a
third mitochondrial GPAT isoform exists. Although, additional GPAT isoenzymes in the
heart could have partially substituted for the function of GPAT1, the changes in TAG
content and phospholipid composition in hearts from both high-sucrose and high-fat fed
mice strongly suggest that cardiomyocyte GPAT1 contributes significantly to the synthesis
of TAG and phospholipids and to the storage of TAG.
Our data are consistent with the hypothesis that each GPAT isoenzyme has a distinct
function within the cell. Several other functionally distinct isoforms have been described in
glycerolipid synthesis, including 1-acyl-glycerol-3-phosphate acyltransferase-2 (AGPAT2)
[52], and diacylglycerol acyltransferases-1 and -2 [53,54]. The phenotype of mice or humans
deficient in each of these activities shows that the presence of catalytically similar isoforms
does not functionally replace the missing enzyme and suggests that each isoform plays a
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Figure 1. Hearts from Gpat1−/− mice lack Gpat1 mRNA, but retain an NEM-resistant GPAT
activity
A: RNA was isolated from backcrossed Bl/6 wildtype (+/+), heterozygous (+/−), and
knockout (−/−) Gpat1 mouse hearts (n = 2) and analyzed for the presence or absence of neo
and Gpat1 transcripts by reverse transcriptase PCR as described in Materials and Methods.
The first lane contains DNA size markers (from top: 1000, 850, and 650 bp). The second
lane (C) is a no template control reaction. Heart total membranes (B) and mitochondria (C,
D) from wildtype and Gpat1−/− mice were isolated as described and assayed for GPAT
activity in the absence or presence of (B, C) 1 mM NEM or (D) 0–10 mM NEM. Data not
shown for 5 and 10 mM NEM, as further inhibition was not observed. Data are presented as
the mean ± SD (n = 3 – 4).
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Figure 2. Absence of GPAT1 diminishes myocardial triacylglycerol accumulation
Lipids were extracted from hearts of male and female Bl/6 (A, high sucrose diet) or F2 (B,
high fat diet) mice (n ≥ 6 for each group) and TAG content was determined as described in
Materials and Methods. A: High sucrose (HS) vs control (CT) diet. B: High fat (HF) diet vs
baseline. For hearts from mice at baseline or on the control diet, heart TAG did not differ
between male and female mice. Data are presented as mean ± SD.
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Figure 3. Gpat1−/− mice have lower plasma triacylglycerol than wildtype mice after high
sucrose- or high fat-diet
Plasma lipids were extracted from male and female Bl/6 (A, high sucrose diet) or F2 (B, high
fat diet) mouse hearts and TAG concentration was determined as described in Materials and
Methods. A: High sucrose (HS) vs control (CT) diet. B: High fat (HF) diet vs baseline. Data
are presented as the mean ± SD; n = 6 for each group.
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Figure 4. Male and female Gpat1−/− mice have lower VLDL secretion rates than wildtype mice
after 2 week high sucrose diet
After a 4 h fast, male (A) and female (B) wildtype and Gpat1 null Bl/6 mice were injected
with Tyloxapol as described in Materials and Methods and plasma was collected at the times
shown. Rates of VLDL secretion were calculated as the concentration of TAG (mg/dl) per
unit of liver weight (g) per hour. Data are presented as the mean ± SD; n ≥ 5 for each group.
Lewin et al. Page 17













Figure 5. Absence of GPAT1 decreases [14C]palmitate incorporation into heart triacylglycerol in
vivo
Wildtype and Gpat1−/− mice were fed a high-sucrose diet for 2 wks and injected with
[14C]palmitate complexed to BSA as described in Materials and Methods. Heart lipids were
extracted and separated by TLC and the amount of [14C] incorporated into TAG was
quantified by Bioscan analysis. Data are presented as cpm [14C] incorporated into TAG/g
protein/cpm [14C] in plasma; n = 3.
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Figure 6. Absence of GPAT1 alters heart phospholipid fatty acid composition
Lipids were extracted from hearts and plasma of F2 female wildtype (+/+) and Gpat1−/− (−/
−) mice (n = 4/genotype) and fatty acid composition was determined as described in
Materials and Methods. A, phosphatidylcholine (PC); B, phosphatidylethanolamine (PE);
phosphatidylserine (PS) and phosphatidylinositol (PI); D, cardiolipin (CL) E, plasma TAG.
Data are presented as mean ± SD. *P ≤ 0.05 relative to wildtype control.
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